Clinical trials for Medullary thyroid carcinoma
17 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 3NCT07383246CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTCCancer Institute and Hospital, Chinese Academy of Medical Sciences · PI: Shaoyan Liu, MD
- RECRUITINGN/ANCT07138716Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTCLuo Yaping · PI: Yaping LUO
- ENROLLING BY INVITATIONNCT06852144PET-TC in Thyroid EvaluationIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGN/ANCT06141369Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)Shanghai Jiao Tong University School of Medicine
- RECRUITINGN/ANCT0627718068Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTCCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGPhase 1NCT06520319Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid CarcinomaFirst Affiliated Hospital of Fujian Medical University · PI: Weibing Miao
- RECRUITINGPhase 4NCT05830500Study of Anlotinib in Patients With Advanced Medullary Thyroid CarcinomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- ACTIVE NOT RECRUITINGPhase 1NCT04877613GFRα4 CAR T Cells in MTC PatientsUniversity of Pennsylvania · PI: Roger Cohen, MD
- ACTIVE NOT RECRUITINGN/ANCT04522570Thermal Ablation of Cervical Metastases From Thyroid CarcinomaInstituto do Cancer do Estado de São Paulo · PI: Ricardo MC Freitas, PhD
- ACTIVE NOT RECRUITINGPhase 3NCT04211337A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerLoxo Oncology, Inc. · PI: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM
- RECRUITINGNCT04216732Natural History of Medullary Thyroid Cancer to Inform Advanced Disease ManagementM.D. Anderson Cancer Center · PI: Elizabeth G Grubbs
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03899792A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsEli Lilly and Company · PI: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
- RECRUITINGN/ANCT03892993Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their CaregiversM.D. Anderson Cancer Center · PI: Elizabeth G Grubbs, MD
- ACTIVE NOT RECRUITINGPhase 2NCT02657551A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid CancerDana-Farber Cancer Institute · PI: Kartik Seghal, MD
- ACTIVE NOT RECRUITINGPhase 4NCT01896479A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid CancerExelixis
- RECRUITINGNCT01660984Natural History Study of Children and Adults With Medullary Thyroid CancerNational Cancer Institute (NCI) · PI: John W Glod, M.D.
- RECRUITINGNCT01109420Clinical and Genetic Studies in Familial Non-medullary Thyroid CancerNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · PI: Joanna Klubo-Gwiezdzinska, M.D.